GENEVA (Reuters) - The World Health Organization will resume its trial of hydroxychloroquine for potential use against the coronavirus, its chief said on Wednesday, after those running the study briefly stopped giving it to new patients over health concerns.
The U.N. agency last month paused the part of its large study of treatments against COVID-19 in which newly enrolled patients were getting the anti-malarial drug to treat COVID-19 due to fears it increased death rates and irregular heartbeats.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!